Good morning. It’s a big day ahead for us here at Port Phillip Publishing.
Because we’re finally ready to release Ryan Dinse’s long-awaited research dossier on something called Project: Shivom.
We’re breaking completely new ground here.
No one, to my knowledge, is following this avenue of research. Or the four stocks Ryan’s attached to it.
You may have missed the first wave of vertical share price rises from the genomic revolution.
These all came in the last 15 years, after the completion of the Human Genome project in 2003.
A second ‘Great Genomic Project’ is underway.
It’s called Project: Shivom.
What is Project: Shivom?
It is, in the words of its creators, going to usher in ‘an unprecedented era of medical marvels’.
A 2016 paper from Deloitte says it ‘has the potential to transform health care, placing the patient at the centre of the health care ecosystem’…
Medical Futurist reports that it ‘will soon create a genomic data market worth billions of dollars’.
And here’s something that should get your Spidey senses tingling…
The guru of modern genomics — and Godfather of The Human Genome Project himself, George M Church — has created his own start-up to take full advantage.
And yet…and this is crucial…it is a long way, perhaps one–two years, from seeping into the mainstream consciousness.
It’s only technologists, biotech geeks and blockchain evangelists that are talking about what I’m about to show you.
And THAT, as a speculative investor, is your advantage…
What are the potential returns?
If Ryan is right, this could be like going back to 2002 and 2003 and investing in the then-unheard of genomic trailblazers, like Illumina.
(Which then went on to rise 28,198%…)
But again, just like with the Human Genome Project, not every spin-off stock will be a winner.
There will be fakers and there will be failures.
You need to use your brain. Think big, think strategic, and think several moves ahead of everyone else.
But crucially, once you’ve picked your plays, you need to move now.
This is not a story that will stay in the shadows for long.
Just like the Human Genome Project, Ryan believes that by mid-2019, you’ll be seeing a 60 Minutes special devoted to this new medical moon-shot.
He has selected three (and a tentative fourth) very small companies he believes could become leading lights — and household names — in the second phase of the genomic revolution.
They are right at the heart of this new Great Project.
They are both driving it and feeding off it.
They are masters of the new technology behind it.
Ryan believes they are the four most tantalising stock speculations on the planet right now.
Across all markets. And all sectors.
But do not take him on his word.
Publisher, Port Phillip Publishing